Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OTLK | PRESS-RELEASE | bearish | 6/10 | Outlook Therapeutics announced a best-efforts public offering of common stock or pre-funded warrants, along with accompa | Mar 23, 2026 |
| TNXP | PRESS-RELEASE | neutral | 5/10 | Tonix Pharmaceuticals presented Phase 1 data for TNX-4800, a long-acting monoclonal antibody for seasonal prevention of | Mar 23, 2026 |
| VOR | PRESS-RELEASE | neutral | 3/10 | Vor Bio granted stock options and RSUs to 8 new employees as inducement awards under its 2023 Inducement Plan. The award | Mar 23, 2026 |
| CNTX | PRESS-RELEASE | mixed | 5/10 | Context Therapeutics reported its 2025 financial results, showing increased R&D spending and a wider net loss, while cas | Mar 23, 2026 |
| ABVX | PRESS-RELEASE | mixed | 6/10 | Abivax reported full-year 2025 financial results with a net loss of €336.1 million, driven by higher R&D and G&A expense | Mar 23, 2026 |
| AARD | PRESS-RELEASE | bearish | 8/10 | Aardvark Therapeutics has voluntarily paused its Phase 3 trials for ARD-101 in Prader-Willi Syndrome and related obesity | Mar 23, 2026 |
| STRO | PRESS-RELEASE | bullish | 7/10 | Sutro Biopharma reported its 2025 financial results, highlighted by a 65% year-over-year increase in revenue to $102.5 m | Mar 23, 2026 |
| SRZN | PRESS-RELEASE | mixed | 6/10 | Surrozen reported its 2025 financial results, showing a significant increase in net loss to $242.0 million due to non-ca | Mar 23, 2026 |
| APGE | PRESS-RELEASE | bearish | 7/10 | Apogee Therapeutics (APGE) has announced a $300 million public offering of common stock, with an additional $45 million | Mar 23, 2026 |
| TRIB | PRESS-RELEASE | bullish | 7/10 | Trinity Biotech announced successful clinical validation of an enhanced version of its EpiCapture™ prostate cancer test, | Mar 23, 2026 |
| SXTC | PRESS-RELEASE | neutral | 3/10 | China SXT Pharmaceuticals, Inc. (SXTC) announced that its Class A Ordinary Shares will begin trading under the symbol 'S | Mar 23, 2026 |
| RNXT | PRESS-RELEASE | neutral | 5/10 | RenovoRx closed an oversubscribed private placement raising $10 million in gross proceeds through the issuance of 10.6 m | Mar 23, 2026 |
| BCAX | PRESS-RELEASE | neutral | 3/10 | Bicara Therapeutics announced it will report its Q4 and full-year 2025 financial results on March 30, 2026, along with a | Mar 23, 2026 |
| BDRX | PRESS-RELEASE | neutral | 4/10 | Biodexa Pharmaceuticals has partnered with Tanner Pharma Group to launch a global Early Access Program for its investiga | Mar 23, 2026 |
| PCVX | PRESS-RELEASE | neutral | 4/10 | Vaxcyte announced completion of enrollment in the OPUS-1 and OPUS-2 Phase 3 trials for its investigational 31-valent pne | Mar 23, 2026 |
| NBY | PRESS-RELEASE | mixed | 7/10 | NovaBay Pharmaceuticals (NBY) is rebranding as Stablecoin Development Corporation (SDEV) following a $134 million privat | Mar 23, 2026 |
| QNTM | PRESS-RELEASE | bullish | 7/10 | Quantum BioPharma announced the peer-reviewed publication of a clinical trial showing its dietary supplement 'unbuzzd' s | Mar 23, 2026 |
| DMRA | PRESS-RELEASE | neutral | 3/10 | Damora Therapeutics appointed Jennifer Jarrett as CEO and President, effective March 30, 2026, alongside key additions t | Mar 23, 2026 |
| HUMA | PRESS-RELEASE | neutral | 3/10 | Humacyte announced it will release its Q4 and full-year 2025 financial results on March 27, 2026, followed by a manageme | Mar 23, 2026 |
| CGTX | PRESS-RELEASE | neutral | 3/10 | Cognition Therapeutics (CGTX) announced it will release Q4 and full-year 2025 financial results on March 26, 2026, follo | Mar 23, 2026 |
| CABA | PRESS-RELEASE | neutral | 5/10 | Cabaletta Bio reported Q4 and full-year 2025 financial results, highlighted by increased R&D spending and a cash positio | Mar 23, 2026 |
| AVXL | PRESS-RELEASE | bullish | 8/10 | Anavex Life Sciences presented long-term clinical data at AD/PD™ 2026 showing that oral blarcamesine is associated with | Mar 23, 2026 |
| PVLA | PRESS-RELEASE | neutral | 4/10 | Palvella Therapeutics announced the appointment of Jennifer McDonough as Senior Vice President of Market Access and Pati | Mar 23, 2026 |
| LXRX | PRESS-RELEASE | bullish | 7/10 | Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a Phase 1 clinical trial for LX9851, a first-in-class | Mar 23, 2026 |
| ABUS | PRESS-RELEASE | bullish | 9/10 | Arbutus Biopharma reported improved financials for 2025 with a narrowed net loss and strong cash position, driven by cos | Mar 23, 2026 |
| XLO | PRESS-RELEASE | bullish | 8/10 | Xilio Therapeutics reported strong financial results for Q4 and full year 2025, driven by a $17.5M milestone from Gilead | Mar 23, 2026 |
| PYXS | PRESS-RELEASE | mixed | 6/10 | Pyxis Oncology reported financial results for 2025 and provided a clinical update on its lead asset, micvotabart pelidot | Mar 23, 2026 |
| AVTX | PRESS-RELEASE | bearish | 6/10 | Avalo Therapeutics reported its 2025 financial results, highlighting a net loss of $78.3 million amid increased R&D spen | Mar 23, 2026 |
| APGE | PRESS-RELEASE | bullish | 8/10 | Apogee Therapeutics announced positive 52-week maintenance data from Part A of its Phase 2 APEX trial for zumilokibart ( | Mar 23, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED has initiated a registrational Phase III trial for HMPL-760, a third-generation BTK inhibitor, in combination w | Mar 22, 2026 |